nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ABCG2—Leflunomide—systemic scleroderma	0.102	0.163	CbGbCtD
Lansoprazole—CYP2C8—Mometasone—systemic scleroderma	0.0843	0.135	CbGbCtD
Lansoprazole—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.063	0.101	CbGbCtD
Lansoprazole—CYP1A2—Pentoxifylline—systemic scleroderma	0.0441	0.0707	CbGbCtD
Lansoprazole—CYP1A2—Leflunomide—systemic scleroderma	0.0421	0.0674	CbGbCtD
Lansoprazole—ABCB1—Lisinopril—systemic scleroderma	0.0386	0.0618	CbGbCtD
Lansoprazole—CYP2C9—Leflunomide—systemic scleroderma	0.0379	0.0607	CbGbCtD
Lansoprazole—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0336	0.0538	CbGbCtD
Lansoprazole—ABCB1—Captopril—systemic scleroderma	0.0289	0.0463	CbGbCtD
Lansoprazole—CYP2D6—Captopril—systemic scleroderma	0.0272	0.0436	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—systemic scleroderma	0.0253	0.0405	CbGbCtD
Lansoprazole—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0227	0.0364	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—systemic scleroderma	0.0225	0.0361	CbGbCtD
Lansoprazole—ABCB1—Prednisone—systemic scleroderma	0.0182	0.0291	CbGbCtD
Lansoprazole—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0136	0.0218	CbGbCtD
Lansoprazole—CYP3A4—Prednisone—systemic scleroderma	0.0109	0.0174	CbGbCtD
Lansoprazole—CYP2C9—cardial valve—systemic scleroderma	0.00982	0.309	CbGeAlD
Lansoprazole—ABCB1—Methotrexate—systemic scleroderma	0.00911	0.0146	CbGbCtD
Lansoprazole—ATP4B—digestive system—systemic scleroderma	0.0036	0.113	CbGeAlD
Lansoprazole—ATP4A—connective tissue—systemic scleroderma	0.00217	0.0683	CbGeAlD
Lansoprazole—MAPT—tendon—systemic scleroderma	0.00201	0.0632	CbGeAlD
Lansoprazole—CYP4A11—digestive system—systemic scleroderma	0.00195	0.0612	CbGeAlD
Lansoprazole—ATP4A—digestive system—systemic scleroderma	0.00157	0.0493	CbGeAlD
Lansoprazole—CYP2C18—digestive system—systemic scleroderma	0.00129	0.0405	CbGeAlD
Lansoprazole—CYP1B1—connective tissue—systemic scleroderma	0.000865	0.0272	CbGeAlD
Lansoprazole—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000791	0.0249	CbGeAlD
Lansoprazole—CYP1B1—skin of body—systemic scleroderma	0.000781	0.0245	CbGeAlD
Lansoprazole—CYP1B1—digestive system—systemic scleroderma	0.000625	0.0196	CbGeAlD
Lansoprazole—ABCB1—blood vessel—systemic scleroderma	0.000619	0.0195	CbGeAlD
Lansoprazole—CYP1B1—tendon—systemic scleroderma	0.000594	0.0187	CbGeAlD
Lansoprazole—CYP1A1—skin of body—systemic scleroderma	0.000552	0.0173	CbGeAlD
Lansoprazole—CYP2C19—digestive system—systemic scleroderma	0.000548	0.0172	CbGeAlD
Lansoprazole—CYP1B1—lung—systemic scleroderma	0.000522	0.0164	CbGeAlD
Lansoprazole—CYP1A2—digestive system—systemic scleroderma	0.000448	0.0141	CbGeAlD
Lansoprazole—CYP1A1—digestive system—systemic scleroderma	0.000442	0.0139	CbGeAlD
Lansoprazole—CYP2C9—digestive system—systemic scleroderma	0.000425	0.0134	CbGeAlD
Lansoprazole—ABCG2—lung—systemic scleroderma	0.000388	0.0122	CbGeAlD
Lansoprazole—CYP1A2—lung—systemic scleroderma	0.000374	0.0117	CbGeAlD
Lansoprazole—CYP1A1—lung—systemic scleroderma	0.000369	0.0116	CbGeAlD
Lansoprazole—CYP3A4—digestive system—systemic scleroderma	0.000324	0.0102	CbGeAlD
Lansoprazole—CYP2D6—digestive system—systemic scleroderma	0.000319	0.01	CbGeAlD
Lansoprazole—ABCB1—digestive system—systemic scleroderma	0.000229	0.00721	CbGeAlD
Lansoprazole—ABCB1—lung—systemic scleroderma	0.000192	0.00602	CbGeAlD
Lansoprazole—Breast disorder—Methotrexate—systemic scleroderma	0.000109	0.000316	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000109	0.000315	CcSEcCtD
Lansoprazole—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000315	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000108	0.000315	CcSEcCtD
Lansoprazole—Hypersensitivity—Azathioprine—systemic scleroderma	0.000108	0.000314	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000108	0.000314	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000314	CcSEcCtD
Lansoprazole—Insomnia—Lisinopril—systemic scleroderma	0.000108	0.000313	CcSEcCtD
Lansoprazole—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000313	CcSEcCtD
Lansoprazole—Paraesthesia—Lisinopril—systemic scleroderma	0.000107	0.000311	CcSEcCtD
Lansoprazole—Vomiting—Captopril—systemic scleroderma	0.000107	0.000311	CcSEcCtD
Lansoprazole—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00031	CcSEcCtD
Lansoprazole—Dyspnoea—Lisinopril—systemic scleroderma	0.000106	0.000309	CcSEcCtD
Lansoprazole—Rash—Captopril—systemic scleroderma	0.000106	0.000308	CcSEcCtD
Lansoprazole—Dermatitis—Captopril—systemic scleroderma	0.000106	0.000308	CcSEcCtD
Lansoprazole—Somnolence—Lisinopril—systemic scleroderma	0.000106	0.000308	CcSEcCtD
Lansoprazole—Headache—Captopril—systemic scleroderma	0.000105	0.000306	CcSEcCtD
Lansoprazole—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000306	CcSEcCtD
Lansoprazole—Dyspepsia—Lisinopril—systemic scleroderma	0.000105	0.000305	CcSEcCtD
Lansoprazole—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000105	0.000304	CcSEcCtD
Lansoprazole—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000105	0.000304	CcSEcCtD
Lansoprazole—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000303	CcSEcCtD
Lansoprazole—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000303	CcSEcCtD
Lansoprazole—Asthma—Methotrexate—systemic scleroderma	0.000104	0.000302	CcSEcCtD
Lansoprazole—Infection—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000301	CcSEcCtD
Lansoprazole—Decreased appetite—Lisinopril—systemic scleroderma	0.000104	0.000301	CcSEcCtD
Lansoprazole—Eosinophilia—Methotrexate—systemic scleroderma	0.000103	0.000299	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000103	0.000299	CcSEcCtD
Lansoprazole—Fatigue—Lisinopril—systemic scleroderma	0.000103	0.000299	CcSEcCtD
Lansoprazole—Shock—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000298	CcSEcCtD
Lansoprazole—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000298	CcSEcCtD
Lansoprazole—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000297	CcSEcCtD
Lansoprazole—Hypersensitivity—Leflunomide—systemic scleroderma	0.000102	0.000297	CcSEcCtD
Lansoprazole—Pancreatitis—Methotrexate—systemic scleroderma	0.000102	0.000296	CcSEcCtD
Lansoprazole—Pain—Lisinopril—systemic scleroderma	0.000102	0.000296	CcSEcCtD
Lansoprazole—Constipation—Lisinopril—systemic scleroderma	0.000102	0.000296	CcSEcCtD
Lansoprazole—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000296	CcSEcCtD
Lansoprazole—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000295	CcSEcCtD
Lansoprazole—Bradycardia—Prednisone—systemic scleroderma	0.000101	0.000295	CcSEcCtD
Lansoprazole—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000293	CcSEcCtD
Lansoprazole—Diarrhoea—Azathioprine—systemic scleroderma	0.000101	0.000292	CcSEcCtD
Lansoprazole—Nausea—Captopril—systemic scleroderma	0.0001	0.00029	CcSEcCtD
Lansoprazole—Abdominal discomfort—Methotrexate—systemic scleroderma	9.98e-05	0.00029	CcSEcCtD
Lansoprazole—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.96e-05	0.000289	CcSEcCtD
Lansoprazole—Asthenia—Leflunomide—systemic scleroderma	9.96e-05	0.000289	CcSEcCtD
Lansoprazole—Hallucination—Prednisone—systemic scleroderma	9.92e-05	0.000288	CcSEcCtD
Lansoprazole—Pancytopenia—Methotrexate—systemic scleroderma	9.88e-05	0.000287	CcSEcCtD
Lansoprazole—Feeling abnormal—Lisinopril—systemic scleroderma	9.83e-05	0.000285	CcSEcCtD
Lansoprazole—Pruritus—Leflunomide—systemic scleroderma	9.82e-05	0.000285	CcSEcCtD
Lansoprazole—Connective tissue disorder—Prednisone—systemic scleroderma	9.79e-05	0.000284	CcSEcCtD
Lansoprazole—Hypotension—Mycophenolate mofetil—systemic scleroderma	9.76e-05	0.000284	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Lisinopril—systemic scleroderma	9.75e-05	0.000283	CcSEcCtD
Lansoprazole—Dysuria—Methotrexate—systemic scleroderma	9.73e-05	0.000283	CcSEcCtD
Lansoprazole—Neutropenia—Methotrexate—systemic scleroderma	9.73e-05	0.000283	CcSEcCtD
Lansoprazole—Dizziness—Azathioprine—systemic scleroderma	9.72e-05	0.000282	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.67e-05	0.000281	CcSEcCtD
Lansoprazole—Erectile dysfunction—Methotrexate—systemic scleroderma	9.58e-05	0.000278	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.52e-05	0.000276	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Methotrexate—systemic scleroderma	9.5e-05	0.000276	CcSEcCtD
Lansoprazole—Asthenia—Mycophenolic acid—systemic scleroderma	9.5e-05	0.000276	CcSEcCtD
Lansoprazole—Diarrhoea—Leflunomide—systemic scleroderma	9.49e-05	0.000276	CcSEcCtD
Lansoprazole—Urticaria—Lisinopril—systemic scleroderma	9.47e-05	0.000275	CcSEcCtD
Lansoprazole—Insomnia—Mycophenolate mofetil—systemic scleroderma	9.45e-05	0.000274	CcSEcCtD
Lansoprazole—Body temperature increased—Lisinopril—systemic scleroderma	9.43e-05	0.000274	CcSEcCtD
Lansoprazole—Abdominal pain—Lisinopril—systemic scleroderma	9.43e-05	0.000274	CcSEcCtD
Lansoprazole—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	9.38e-05	0.000272	CcSEcCtD
Lansoprazole—Pruritus—Mycophenolic acid—systemic scleroderma	9.37e-05	0.000272	CcSEcCtD
Lansoprazole—Vomiting—Azathioprine—systemic scleroderma	9.34e-05	0.000271	CcSEcCtD
Lansoprazole—Pneumonia—Methotrexate—systemic scleroderma	9.33e-05	0.000271	CcSEcCtD
Lansoprazole—Eye disorder—Prednisone—systemic scleroderma	9.31e-05	0.000271	CcSEcCtD
Lansoprazole—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	9.31e-05	0.00027	CcSEcCtD
Lansoprazole—Somnolence—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.00027	CcSEcCtD
Lansoprazole—Infestation NOS—Methotrexate—systemic scleroderma	9.28e-05	0.000269	CcSEcCtD
Lansoprazole—Infestation—Methotrexate—systemic scleroderma	9.28e-05	0.000269	CcSEcCtD
Lansoprazole—Rash—Azathioprine—systemic scleroderma	9.26e-05	0.000269	CcSEcCtD
Lansoprazole—Dermatitis—Azathioprine—systemic scleroderma	9.26e-05	0.000269	CcSEcCtD
Lansoprazole—Headache—Azathioprine—systemic scleroderma	9.2e-05	0.000267	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	9.2e-05	0.000267	CcSEcCtD
Lansoprazole—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	9.2e-05	0.000267	CcSEcCtD
Lansoprazole—Dizziness—Leflunomide—systemic scleroderma	9.18e-05	0.000266	CcSEcCtD
Lansoprazole—Renal failure—Methotrexate—systemic scleroderma	9.12e-05	0.000265	CcSEcCtD
Lansoprazole—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	9.08e-05	0.000264	CcSEcCtD
Lansoprazole—Diarrhoea—Mycophenolic acid—systemic scleroderma	9.06e-05	0.000263	CcSEcCtD
Lansoprazole—Stomatitis—Methotrexate—systemic scleroderma	9.04e-05	0.000263	CcSEcCtD
Lansoprazole—Angiopathy—Prednisone—systemic scleroderma	9.04e-05	0.000263	CcSEcCtD
Lansoprazole—Conjunctivitis—Methotrexate—systemic scleroderma	9.02e-05	0.000262	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	9.02e-05	0.000262	CcSEcCtD
Lansoprazole—Immune system disorder—Prednisone—systemic scleroderma	9e-05	0.000261	CcSEcCtD
Lansoprazole—Constipation—Mycophenolate mofetil—systemic scleroderma	8.93e-05	0.000259	CcSEcCtD
Lansoprazole—Pain—Mycophenolate mofetil—systemic scleroderma	8.93e-05	0.000259	CcSEcCtD
Lansoprazole—Arrhythmia—Prednisone—systemic scleroderma	8.9e-05	0.000259	CcSEcCtD
Lansoprazole—Sweating—Methotrexate—systemic scleroderma	8.9e-05	0.000258	CcSEcCtD
Lansoprazole—Haematuria—Methotrexate—systemic scleroderma	8.85e-05	0.000257	CcSEcCtD
Lansoprazole—Vomiting—Leflunomide—systemic scleroderma	8.82e-05	0.000256	CcSEcCtD
Lansoprazole—Alopecia—Prednisone—systemic scleroderma	8.81e-05	0.000256	CcSEcCtD
Lansoprazole—Hypersensitivity—Lisinopril—systemic scleroderma	8.78e-05	0.000255	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Methotrexate—systemic scleroderma	8.78e-05	0.000255	CcSEcCtD
Lansoprazole—Dizziness—Mycophenolic acid—systemic scleroderma	8.75e-05	0.000254	CcSEcCtD
Lansoprazole—Epistaxis—Methotrexate—systemic scleroderma	8.75e-05	0.000254	CcSEcCtD
Lansoprazole—Rash—Leflunomide—systemic scleroderma	8.75e-05	0.000254	CcSEcCtD
Lansoprazole—Dermatitis—Leflunomide—systemic scleroderma	8.74e-05	0.000254	CcSEcCtD
Lansoprazole—Mental disorder—Prednisone—systemic scleroderma	8.73e-05	0.000254	CcSEcCtD
Lansoprazole—Nausea—Azathioprine—systemic scleroderma	8.73e-05	0.000253	CcSEcCtD
Lansoprazole—Headache—Leflunomide—systemic scleroderma	8.69e-05	0.000252	CcSEcCtD
Lansoprazole—Malnutrition—Prednisone—systemic scleroderma	8.68e-05	0.000252	CcSEcCtD
Lansoprazole—Erythema—Prednisone—systemic scleroderma	8.68e-05	0.000252	CcSEcCtD
Lansoprazole—Agranulocytosis—Methotrexate—systemic scleroderma	8.66e-05	0.000251	CcSEcCtD
Lansoprazole—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.61e-05	0.00025	CcSEcCtD
Lansoprazole—Asthenia—Lisinopril—systemic scleroderma	8.55e-05	0.000248	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.54e-05	0.000248	CcSEcCtD
Lansoprazole—Pruritus—Lisinopril—systemic scleroderma	8.44e-05	0.000245	CcSEcCtD
Lansoprazole—Vomiting—Mycophenolic acid—systemic scleroderma	8.42e-05	0.000244	CcSEcCtD
Lansoprazole—Rash—Mycophenolic acid—systemic scleroderma	8.35e-05	0.000242	CcSEcCtD
Lansoprazole—Dermatitis—Mycophenolic acid—systemic scleroderma	8.34e-05	0.000242	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—systemic scleroderma	8.33e-05	0.000242	CcSEcCtD
Lansoprazole—Urticaria—Mycophenolate mofetil—systemic scleroderma	8.3e-05	0.000241	CcSEcCtD
Lansoprazole—Headache—Mycophenolic acid—systemic scleroderma	8.29e-05	0.000241	CcSEcCtD
Lansoprazole—Pharyngitis—Methotrexate—systemic scleroderma	8.27e-05	0.00024	CcSEcCtD
Lansoprazole—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	8.26e-05	0.00024	CcSEcCtD
Lansoprazole—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.26e-05	0.00024	CcSEcCtD
Lansoprazole—Nausea—Leflunomide—systemic scleroderma	8.24e-05	0.000239	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—systemic scleroderma	8.23e-05	0.000239	CcSEcCtD
Lansoprazole—Vision blurred—Prednisone—systemic scleroderma	8.18e-05	0.000237	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—systemic scleroderma	8.17e-05	0.000237	CcSEcCtD
Lansoprazole—Diarrhoea—Lisinopril—systemic scleroderma	8.16e-05	0.000237	CcSEcCtD
Lansoprazole—Ill-defined disorder—Prednisone—systemic scleroderma	8.05e-05	0.000234	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—systemic scleroderma	8.03e-05	0.000233	CcSEcCtD
Lansoprazole—Anaemia—Prednisone—systemic scleroderma	8.02e-05	0.000233	CcSEcCtD
Lansoprazole—Agitation—Prednisone—systemic scleroderma	7.97e-05	0.000232	CcSEcCtD
Lansoprazole—Angioedema—Prednisone—systemic scleroderma	7.93e-05	0.00023	CcSEcCtD
Lansoprazole—Dizziness—Lisinopril—systemic scleroderma	7.88e-05	0.000229	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—systemic scleroderma	7.88e-05	0.000229	CcSEcCtD
Lansoprazole—Nausea—Mycophenolic acid—systemic scleroderma	7.86e-05	0.000228	CcSEcCtD
Lansoprazole—Malaise—Prednisone—systemic scleroderma	7.82e-05	0.000227	CcSEcCtD
Lansoprazole—Vertigo—Prednisone—systemic scleroderma	7.8e-05	0.000226	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—systemic scleroderma	7.78e-05	0.000226	CcSEcCtD
Lansoprazole—Syncope—Prednisone—systemic scleroderma	7.78e-05	0.000226	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—systemic scleroderma	7.77e-05	0.000226	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—systemic scleroderma	7.73e-05	0.000225	CcSEcCtD
Lansoprazole—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000224	CcSEcCtD
Lansoprazole—Loss of consciousness—Prednisone—systemic scleroderma	7.63e-05	0.000221	CcSEcCtD
Lansoprazole—Vomiting—Lisinopril—systemic scleroderma	7.58e-05	0.00022	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—systemic scleroderma	7.56e-05	0.000219	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—systemic scleroderma	7.52e-05	0.000219	CcSEcCtD
Lansoprazole—Rash—Lisinopril—systemic scleroderma	7.52e-05	0.000218	CcSEcCtD
Lansoprazole—Convulsion—Prednisone—systemic scleroderma	7.52e-05	0.000218	CcSEcCtD
Lansoprazole—Dermatitis—Lisinopril—systemic scleroderma	7.51e-05	0.000218	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—systemic scleroderma	7.51e-05	0.000218	CcSEcCtD
Lansoprazole—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.5e-05	0.000218	CcSEcCtD
Lansoprazole—Hypertension—Prednisone—systemic scleroderma	7.49e-05	0.000218	CcSEcCtD
Lansoprazole—Chills—Methotrexate—systemic scleroderma	7.47e-05	0.000217	CcSEcCtD
Lansoprazole—Headache—Lisinopril—systemic scleroderma	7.47e-05	0.000217	CcSEcCtD
Lansoprazole—Pruritus—Mycophenolate mofetil—systemic scleroderma	7.39e-05	0.000215	CcSEcCtD
Lansoprazole—Myalgia—Prednisone—systemic scleroderma	7.39e-05	0.000215	CcSEcCtD
Lansoprazole—Arthralgia—Prednisone—systemic scleroderma	7.39e-05	0.000215	CcSEcCtD
Lansoprazole—Anxiety—Prednisone—systemic scleroderma	7.36e-05	0.000214	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—systemic scleroderma	7.36e-05	0.000214	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.34e-05	0.000213	CcSEcCtD
Lansoprazole—Discomfort—Prednisone—systemic scleroderma	7.3e-05	0.000212	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—systemic scleroderma	7.3e-05	0.000212	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—systemic scleroderma	7.25e-05	0.000211	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—systemic scleroderma	7.25e-05	0.000211	CcSEcCtD
Lansoprazole—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.15e-05	0.000208	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—systemic scleroderma	7.1e-05	0.000206	CcSEcCtD
Lansoprazole—Nausea—Lisinopril—systemic scleroderma	7.08e-05	0.000206	CcSEcCtD
Lansoprazole—Oedema—Prednisone—systemic scleroderma	7.08e-05	0.000206	CcSEcCtD
Lansoprazole—Anaphylactic shock—Prednisone—systemic scleroderma	7.08e-05	0.000206	CcSEcCtD
Lansoprazole—Infection—Prednisone—systemic scleroderma	7.03e-05	0.000204	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—systemic scleroderma	7.01e-05	0.000204	CcSEcCtD
Lansoprazole—Shock—Prednisone—systemic scleroderma	6.97e-05	0.000202	CcSEcCtD
Lansoprazole—Nervous system disorder—Prednisone—systemic scleroderma	6.94e-05	0.000202	CcSEcCtD
Lansoprazole—Tachycardia—Prednisone—systemic scleroderma	6.91e-05	0.000201	CcSEcCtD
Lansoprazole—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.91e-05	0.000201	CcSEcCtD
Lansoprazole—Skin disorder—Prednisone—systemic scleroderma	6.88e-05	0.0002	CcSEcCtD
Lansoprazole—Hyperhidrosis—Prednisone—systemic scleroderma	6.85e-05	0.000199	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—systemic scleroderma	6.83e-05	0.000198	CcSEcCtD
Lansoprazole—Anorexia—Prednisone—systemic scleroderma	6.75e-05	0.000196	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—systemic scleroderma	6.73e-05	0.000195	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—systemic scleroderma	6.7e-05	0.000195	CcSEcCtD
Lansoprazole—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.64e-05	0.000193	CcSEcCtD
Lansoprazole—Rash—Mycophenolate mofetil—systemic scleroderma	6.59e-05	0.000191	CcSEcCtD
Lansoprazole—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.58e-05	0.000191	CcSEcCtD
Lansoprazole—Headache—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.00019	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—systemic scleroderma	6.54e-05	0.00019	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—systemic scleroderma	6.51e-05	0.000189	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—systemic scleroderma	6.49e-05	0.000189	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.45e-05	0.000187	CcSEcCtD
Lansoprazole—Insomnia—Prednisone—systemic scleroderma	6.4e-05	0.000186	CcSEcCtD
Lansoprazole—Paraesthesia—Prednisone—systemic scleroderma	6.36e-05	0.000185	CcSEcCtD
Lansoprazole—Cough—Methotrexate—systemic scleroderma	6.33e-05	0.000184	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—systemic scleroderma	6.28e-05	0.000182	CcSEcCtD
Lansoprazole—Dyspepsia—Prednisone—systemic scleroderma	6.23e-05	0.000181	CcSEcCtD
Lansoprazole—Nausea—Mycophenolate mofetil—systemic scleroderma	6.21e-05	0.00018	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—systemic scleroderma	6.17e-05	0.000179	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—systemic scleroderma	6.17e-05	0.000179	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—systemic scleroderma	6.17e-05	0.000179	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—systemic scleroderma	6.16e-05	0.000179	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	6.13e-05	0.000178	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—systemic scleroderma	6.1e-05	0.000177	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—systemic scleroderma	6.1e-05	0.000177	CcSEcCtD
Lansoprazole—Constipation—Prednisone—systemic scleroderma	6.06e-05	0.000176	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—systemic scleroderma	5.97e-05	0.000173	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—systemic scleroderma	5.92e-05	0.000172	CcSEcCtD
Lansoprazole—Infection—Methotrexate—systemic scleroderma	5.88e-05	0.000171	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisone—systemic scleroderma	5.84e-05	0.000169	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—systemic scleroderma	5.8e-05	0.000169	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—systemic scleroderma	5.79e-05	0.000168	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Prednisone—systemic scleroderma	5.79e-05	0.000168	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—systemic scleroderma	5.75e-05	0.000167	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—systemic scleroderma	5.72e-05	0.000166	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—systemic scleroderma	5.64e-05	0.000164	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—systemic scleroderma	5.63e-05	0.000163	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—systemic scleroderma	5.6e-05	0.000163	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—systemic scleroderma	5.6e-05	0.000163	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—systemic scleroderma	5.53e-05	0.000161	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.39e-05	0.000157	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—systemic scleroderma	5.35e-05	0.000155	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—systemic scleroderma	5.31e-05	0.000154	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—systemic scleroderma	5.28e-05	0.000153	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—systemic scleroderma	5.26e-05	0.000153	CcSEcCtD
Lansoprazole—Hypersensitivity—Prednisone—systemic scleroderma	5.22e-05	0.000152	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—systemic scleroderma	5.21e-05	0.000151	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—systemic scleroderma	5.14e-05	0.000149	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.11e-05	0.000148	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—systemic scleroderma	5.1e-05	0.000148	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—systemic scleroderma	5.08e-05	0.000148	CcSEcCtD
Lansoprazole—Pain—Methotrexate—systemic scleroderma	5.06e-05	0.000147	CcSEcCtD
Lansoprazole—Pruritus—Prednisone—systemic scleroderma	5.01e-05	0.000146	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—systemic scleroderma	4.88e-05	0.000142	CcSEcCtD
Lansoprazole—Diarrhoea—Prednisone—systemic scleroderma	4.84e-05	0.000141	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.84e-05	0.000141	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—systemic scleroderma	4.7e-05	0.000137	CcSEcCtD
Lansoprazole—Dizziness—Prednisone—systemic scleroderma	4.68e-05	0.000136	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—systemic scleroderma	4.68e-05	0.000136	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—systemic scleroderma	4.68e-05	0.000136	CcSEcCtD
Lansoprazole—Vomiting—Prednisone—systemic scleroderma	4.5e-05	0.000131	CcSEcCtD
Lansoprazole—Rash—Prednisone—systemic scleroderma	4.46e-05	0.00013	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—systemic scleroderma	4.46e-05	0.00013	CcSEcCtD
Lansoprazole—Headache—Prednisone—systemic scleroderma	4.44e-05	0.000129	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—systemic scleroderma	4.36e-05	0.000127	CcSEcCtD
Lansoprazole—Asthenia—Methotrexate—systemic scleroderma	4.25e-05	0.000123	CcSEcCtD
Lansoprazole—Nausea—Prednisone—systemic scleroderma	4.21e-05	0.000122	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—systemic scleroderma	4.19e-05	0.000122	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—systemic scleroderma	4.05e-05	0.000118	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—systemic scleroderma	3.91e-05	0.000114	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—systemic scleroderma	3.76e-05	0.000109	CcSEcCtD
Lansoprazole—Rash—Methotrexate—systemic scleroderma	3.73e-05	0.000108	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—systemic scleroderma	3.73e-05	0.000108	CcSEcCtD
Lansoprazole—Headache—Methotrexate—systemic scleroderma	3.71e-05	0.000108	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—systemic scleroderma	3.52e-05	0.000102	CcSEcCtD
